Sign In
NewsRadar

Immutep S.A.

Immutep develops T-cell response-based immunotherapeutics against cancer and infectious diseases.

• Show past press releases
• Edit this company

Contact Information
Address:
 
 

Phone:
Fax:
Web:
Contact:
 
 
Faculté de Pharmacie
5 rue Jean-Baptiste Clément
Châtenay-Malabry 92296
France
+33 (0)1 6928 9992
+33 (0)1 6907 8221
http://www.immutep.com
John B. Hawken
+33 (0)1 6928 9992

Company Facts
Founded:Sep 2001
Founders:Frédéric Triebel
CEO:John B. Hawken
CTO or technical lead:Frédéric Triebel
CFO or finance director:
Head of Sales:
Head of Marketing:

Stage:Startup
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:
Profitability:
Funding raised:Yes
Funding sought:
Seeking Partnerships:

Non-executive Board Members

Key Customers

Key Business Partners

Key Competitors

Capital Raised
DateSizeInvestors
To view this information you must be signed in and subscribed to the online dataservice, sign in here.

To read more about the Online data service click here

Public Offerings
DateTypeExchange
No public offerings


Data


26,140
Tech investments
From our Online Data Service
16,888
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12N/AKnowledge management
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.